In December 2017, the Governor-in-Council published in Canada Gazette Part 1 the most comprehensive changes affecting patented medicines since Bill … Read More

The release of the Patented Medicine Prices Review Board (PMPRB) Annual Report is delayed once again this year – so … Read More

Owing to new developments and growing stakeholder interest, PDCI and H3 have now completed a second private payer PLA survey. … Read More

PHARMACARE COSTING IN CANADA Estimated Costs of Proposed National Pharmacare Programs.

Full report available here.

The objective of this preliminary report is to summarize PDCI’s assessment of the national pharmacare cost estimate study (Morgan et … Read More

Report 4: PLA Perspectives, Comparison and Contrast

Last week Manulife introduced its new DrugWatch™. It has been described by Manulife … Read More

Report 3: Experience Negotiating Private Payer PLAs

PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched the Private Payer Product … Read More

Report 2: Negotiation-Naïve & Interested in Negotiating a Private Payer PLA

PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched … Read More